Stock Price Movement and Market Context
On the trading day, Remedium Lifecare’s stock fell by 10.00%, underperforming its sector by 10.46%. This decline extended a losing streak that has persisted for seven consecutive days, during which the stock has lost approximately 50% of its value. The current price of Rs.0.45 stands well below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum.
In contrast, the broader market has shown resilience. The Sensex opened 414.29 points higher and was trading at 79,545.31, up 0.54% on the day. Despite the Sensex trading below its 50-day moving average, the 50DMA remains above the 200DMA, indicating a generally positive medium-term trend. Mega-cap stocks have been leading the market gains, highlighting a divergence between large-cap and micro-cap performances.
Over the past year, Remedium Lifecare’s stock has delivered a return of -71.85%, significantly lagging the Sensex’s 7.81% gain. The stock’s 52-week high was Rs.1.94, underscoring the steep decline experienced over the last twelve months.
Our latest weekly pick is live! This Large Cap from Diamond & Gold Jewellery comes with clear entry and exit targets. See the detailed report with target price now!
- - Clear entry/exit targets
- - Target price revealed
- - Detailed report available
Financial Performance and Profitability Metrics
Remedium Lifecare’s financial results have reflected a challenging environment. The company reported a sharp decline in net sales, falling by 65.79% in the quarter ending September 2025, with net sales amounting to Rs.8.58 crores. Profit after tax (PAT) for the nine months period stood at a loss of Rs.2.94 crores, representing a decline of 92.82%. The profit before tax excluding other income (PBT less OI) was negative Rs.3.18 crores, a fall of 293.90% compared to previous periods.
Operating profit growth has stagnated over the last five years, with an annual growth rate of 0%, indicating limited expansion in core earnings. The company has reported losses for five consecutive quarters, contributing to a negative return on capital employed (ROCE). This negative ROCE reflects the company’s inability to generate returns from its capital base.
Debt servicing capacity remains a concern, with a Debt to EBITDA ratio of -1.00 times, signalling that earnings before interest, tax, depreciation, and amortisation are insufficient to cover debt obligations. This metric is a key factor in the company’s current strong sell rating, which was upgraded from a sell rating on 9 April 2024 by MarketsMOJO. The Mojo Score stands at 1.0, the lowest possible, reinforcing the cautious stance on the stock.
Valuation and Risk Assessment
The stock is trading at valuations considered risky relative to its historical averages. The sustained negative EBITDA and losses have weighed heavily on investor sentiment and valuation multiples. Over the past year, the stock’s returns of -71.85% have been accompanied by a lack of profit growth, further underscoring the challenges faced by the company.
In addition to underperforming the Sensex, Remedium Lifecare has lagged the BSE500 index over the last three years, one year, and three months, highlighting below-par performance both in the long term and near term. This persistent underperformance has contributed to the stock’s decline to its current 52-week low.
Institutional Shareholding Trends
Despite the stock’s recent performance, institutional investors have marginally increased their stake by 1.7% over the previous quarter, collectively holding 1.7% of the company’s shares. Institutional participation often reflects a more detailed analysis of company fundamentals, although the overall stake remains modest relative to larger companies in the sector.
Considering Remedium Lifecare Ltd? Wait! SwitchER has found potentially better options in Trading & Distributors and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - Trading & Distributors + beyond scope
- - Top-rated alternatives ready
Summary of Key Metrics
To summarise, Remedium Lifecare Ltd’s stock has reached a new low of Rs.0.45, reflecting a significant decline of over 70% in the past year. The company’s financial indicators, including negative EBITDA, declining net sales, and losses over multiple quarters, have contributed to this trend. The Debt to EBITDA ratio of -1.00 times and negative ROCE further highlight the financial stress faced by the company. The Mojo Grade of Strong Sell and a Mojo Score of 1.0 reinforce the cautious outlook on the stock’s current standing.
While the broader market and sector have shown positive momentum, Remedium Lifecare’s share price continues to reflect the challenges embedded in its financial performance and valuation metrics.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
